Analyst Ratings For Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter:
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
What 4 Analyst Ratings Have To Say About Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter:
Morgan Stanley Maintains Overweight on Axonics, Lowers Price Target to $73
Morgan Stanley maintains Axonics (NASDAQ:AXNX) with a Overweight and lowers the price target from $74 to $73.
The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours.
Needham Maintains Buy on Axonics, Lowers Price Target to $71
Needham analyst Mike Matson maintains Axonics (NASDAQ:AXNX) with a Buy and lowers the price target from $78 to $71.
Axonics Modulation Tech Q3 EPS $(0.38) Beats $(0.43) Estimate, Sales $46.90M Miss $48.97M Estimate
Axonics Modulation Tech (NASDAQ:AXNX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.43) by 11.63 percent. This is a 58.33 percent decrease over losses of $(0.24) per
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)